Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.52 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953334 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL9955627 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL538815 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL2566459 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL2494920 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL986357 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL8419701 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL2121084 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL3899957 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT | |
| SCHEMBL4132273 | 1.00 | GPR84 (0.53) | GPR84FFAR1ACE2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119015394-A | Sulfur-containing compound preparation, and preparation method and application thereof | 上海优斐斯生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118431472-A | Binder composition, slurry composition, electrode, and secondary battery | 上海百公里新材料科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-115209866-A | Mixed cosmetic comprising creamy compacted powder | 艺术化妆品有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-1782791-B2 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2019-01-23 | — | — | EP | claimed |
| US-10071040-B2 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | L'OREAL (FR) | 2018-09-11 | — | — | US | claimed |
| EP-2932957-B1 | CLEANSING COSMETICS | NOF CORP (JP) | 2017-07-19 | — | — | EP | claimed |
| EP-2968248-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | Nal Pharmaceuticals Ltd. (CN) | 2016-01-20 | — | — | EP | claimed |
| EP-2932957-A1 | CLEANSING COSMETICS | NOF Corporation (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2014152454-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (CN) | 2014-09-25 | — | — | WO | claimed |
| US-20140271866-A1 | TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING RIVASTIGMINE | NAL PHARMACEUTICALS, LTD. (HK) | 2014-09-18 | — | — | US | claimed |
| EP-1782791-B1 | Cosmetic composition comprising a cationic surfactant,a liquid fatty material and a sorbitan ester | OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-7417162-B2 | Oily ingredient for cosmetic preparation and cosmetic preparation | KYOWA YUKA CO., LTD. (JP) | 2008-08-26 | — | — | US | claimed |
| US-20070122508-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | HELIXIR CO., LTD. (KR) | 2007-05-31 | — | — | US | claimed |
| US-20070104671-A1 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | L'OREAL S.A. (FR) | 2007-05-10 | — | — | US | claimed |
| US-6797374-B2 | MULTILAYER; NONMAGNETIC SUPPORT, MAGNETIC LAYER CONTAINING FATTY ESTER LUBRICANT; DURABILITY, WEAR RESISTANCE | TDK CORPORATION (JP) | 2004-09-28 | — | — | US | claimed |
| US-5905102-A | COAGULATION OF PIGMENTS, DECREASING WRITING DENSITY DUE TO SEDIMENTATION, CLOGGING THE PEN POINTS AND OXIDATION OF CARBON BLACK | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 1999-05-18 | — | — | US | claimed |
| US-12630654-B2 | Emulsion particle-containing aqueous dispersion | NIPPON SHOKUBAI CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122005622-A | Composition for improving, preventing or treating vaginitis or vulvitis comprising lactobacillus salivarius HHuMin-U | 比菲德股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-1993010101-A1 | BENZIMIDAZOLE ANTHELMINTIC AGENTS | PFIZER LIMITED (GB) | 1993-05-27 | — | — | WO | disclosed |
| US-4822417-A | ERASABLE, NONDRYING | PENTEL KABUSHIKI KAISHA (JP) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070104671-A1 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | KRT18, CUTA, CD44 | GPR84 1247/4885FFAR1 127/4885ACE2 4865/4885 |
| US-12630654-B2 | Emulsion particle-containing aqueous dispersion | CLTB, CLTA, APOB | GPR84 2256/4885FFAR1 780/4885ACE2 4516/4885 |
| US-10071040-B2 | Cosmetic composition comprising a cation, a liquid fatty substance and a sorbitan ester, and cosmetic treatment process | KRT18, CUTA, CD44 | GPR84 1247/4885FFAR1 127/4885ACE2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.